Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$166.91 USD
-2.73 (-1.61%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $166.81 -0.10 (-0.06%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
Fundamental Charts
About Return on Equity (TTM)
Charles River Laboratories International, Inc.'s return on equity, or ROE, is 15.19% compared to the ROE of the Medical Services industry of 2.52%. While this shows that CRL makes good use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
CRL 166.91 -2.73(-1.61%)
Will CRL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRL
Analysts Estimate AMN Healthcare Services (AMN) to Report a Decline in Earnings: What to Look Out for
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?
CRL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Charles River Q2 Earnings Preview: What's in Store for the Stock?
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Is it Prudent to Retain Charles River Stock in Your Portfolio Now?
Other News for CRL
CRL Crosses Below Key Moving Average Level
Charles River (CRL) Explores New Partnership for Funding Opportunities
Charles River, BioTech Social to pursue crowdfunding partnership
Charles River and BioTech Social Inc. Pursue Crowdfunding Partnership | CRL Stock News
ClearBridge Growth Fund Q2 2025 Commentary